HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.

Abstract
The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the tumor suppressor protein p53, conferring tumor development and survival. Antagonists targeting the p53-binding domains of MDM2 and MDMX kill tumor cells both in vitro and in vivo by reactivating the p53 pathway, promising a class of antitumor agents for cancer therapy. Aided by native chemical ligation and mirror image phage display, we recently identified a D-peptide inhibitor of the p53-MDM2 interaction termed (D)PMI-alpha (TNWYANLEKLLR) that competes with p53 for MDM2 binding at an affinity of 219 nM. Increased selection stringency resulted in a distinct D-peptide inhibitor termed (D)PMI-gamma (DWWPLAFEALLR) that binds MDM2 at an affinity of 53 nM. Structural studies coupled with mutational analysis verified the mode of action of these D-peptides as MDM2-dependent p53 activators. Despite being resistant to proteolysis, both (D)PMI-alpha and (D)PMI-gamma failed to actively traverse the cell membrane and, when conjugated to a cationic cell-penetrating peptide, were indiscriminately cytotoxic independently of p53 status. When encapsulated in liposomes decorated with an integrin-targeting cyclic-RGD peptide, however, (D)PMI-alpha exerted potent p53-dependent growth inhibitory activity against human glioblastoma in cell cultures and nude mouse xenograft models. Our findings validate D-peptide antagonists of MDM2 as a class of p53 activators for targeted molecular therapy of malignant neoplasms harboring WT p53 and elevated levels of MDM2.
AuthorsMin Liu, Chong Li, Marzena Pazgier, Changqing Li, Yubin Mao, Yifan Lv, Bing Gu, Gang Wei, Weirong Yuan, Changyou Zhan, Wei-Yue Lu, Wuyuan Lu
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 107 Issue 32 Pg. 14321-6 (Aug 10 2010) ISSN: 1091-6490 [Electronic] United States
PMID20660730 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Liposomes
  • Oligopeptides
  • Peptides
  • Tumor Suppressor Protein p53
  • arginyl-glycyl-aspartic acid
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2
Topics
  • Amino Acid Sequence
  • Animals
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Drug Delivery Systems (methods)
  • Drug Screening Assays, Antitumor
  • Glioblastoma (drug therapy, pathology)
  • Humans
  • Liposomes
  • Mice
  • Mice, Nude
  • Oligopeptides
  • Peptides (pharmacology, therapeutic use)
  • Protein Binding (drug effects)
  • Proto-Oncogene Proteins c-mdm2 (metabolism)
  • Transplantation, Heterologous
  • Tumor Suppressor Protein p53 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: